Dr. Agarwal on the CheckMate-214 Trial for Kidney Cancer

Video

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the CheckMate-214 trial for patients with kidney cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the CheckMate-214 trial for patients with kidney cancer.

The treatment in newly diagnosed patients with RCC has undergone a revolution in the last year, according to Agarwal. Until recently, there were only 2 drugs—sunitinib (Sutent) and pazopanib (Votrient), which were considered standard of care for these patients.

The CheckMate-214 trial tested the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) compared with sunitinib. This trial showed an improved overall survival, as well as overall response rates with the combination. The complete response rates were 9% in patients who were treated with the combination. This has the potential to transform the care for these patients, explains Agarwal.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD